ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer

Abstract

Objective

Cisplatin (CDDP)-based chemotherapy is a first-line, drug regimen for muscle-invasive bladder cancer (BC) and metastatic bladder cancer. Clinically, resistance to CDDP restricts the clinical benefit of some bladder cancer patients. AT-rich interaction domain 1A (ARID1A) gene mutation occurs frequently in bladder cancer; however, the role of CDDP sensitivity in BC has not been studied.

Methods

We established ARID1A knockout BC cell lines using CRISPR/Cas9 technology. IC₅₀ determination, flow cytometry analysis of apoptosis, and tumor xenograft assays were performed to verify changes in the CDDP sensitivity of BC cells losing ARID1A. qRT-PCR, Western blotting, RNA interference, bioinformatic analysis, and ChIP-qPCR analysis were performed to further explore the potential mechanism of ARID1A inactivation in CDDP sensitivity in BC.

Results

It was found that ARID1A inactivation was associated with CDDP resistance in BC cells. Mechanically, loss of ARID1A promoted the expression of eukaryotic translation initiation factor 4A3 (EIF4A3) through epigenetic regulation. Increased expression of EIF4A3 promoted the expression of hsa_circ_0008399 (circ0008399), a novel circular RNA (circRNA) identified in our previous study, which, to some extent, showed that ARID1A deletion caused CDDP resistance through the inhibitory effect of circ0008399 on the apoptosis of BC cells. Importantly, EIF4A3-IN-2 specifically inhibited the activity of EIF4A3 to reduce circ0008399 production and restored the sensitivity of ARID1A inactivated BC cells to CDDP.

Conclusion

Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.

Keywords

AT-rich interaction domain 1A / hsa_circ_0008399 / eukaryotic translation initiation factor 4A3 / cisplatin resistance / bladder cancer

References

[1] SungH, FerlayJ, SiegelRL, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249

[2] TavoraF, EpsteinJI. Bladder cancer, pathological classification and staging. BJU Int, 2008, 102(9): 1216-1220 Pt B

[3] Millan-RodriguezF, Chechile-TonioloG, Salvador-BayarriJ, et al.. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol, 2000, 163(1): 73-78

[4] KamounA, de ReyniesA, AlloryY, et al.. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol, 2020, 77(4): 420-433

[5] KamatAM, HegartyPK, GeeJR, et al.. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol, 2013, 63(1): 4-15

[6] WitjesJA, BruinsHM, CathomasR, et al.. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol, 2021, 79(1): 82-104

[7] GalluzziL, SenovillaL, VitaleI, et al.. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15): 1869-83

[8] ValleJW, LamarcaA, GoyalL, et al.. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov, 2017, 7(9): 943-962

[9] LuC, AllisCD. SWI/SNF complex in cancer. Nat Genet, 2017, 49(2): 178-179

[10] WuJN, RobertsCW. ARID1A mutations in cancer: another epigenetic tumor suppressor?. Cancer Discov, 2013, 3(1): 35-43

[11] MathurR, AlverBH, San RomanAK, et al.. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet, 2017, 49(2): 296-302

[12] WuRC, WangTL, ShihI M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther, 2014, 15(6): 655-664

[13] Megino-LuqueC, SisoP, Mota-MartorellN, et al.. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol, 2022, 16(11): 2235-2259

[14] ElkhadragyL, Dasteh GoliK, ToturaWM, et al.. Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma. Front Oncol, 2022, 12: 904031

[15] ShangXY, ShiY, HeDD, et al.. ARID1A deficiency weakens BRG1-RAD21 interaction that jeopardizes chromatin compactness and drives liver cancer cell metastasis. Cell Death Dis, 2021, 12(11): 990

[16] LiuX, DaiSK, LiuPP, et al.. Arid1a regulates neural stem/progenitor cell proliferation and differentiation during cortical development. Cell Prolif, 2021, 54(11): e13124

[17] ZhangFK, NiQZ, WangK, et al.. Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol, 2022, 14(1): 101-127

[18] LyuC, ZhangY, ZhouX, et al.. ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. Exp Ther Med, 2016, 12(6): 4067-4071

[19] NigroJM, ChoKR, FearonER, et al.. Scrambled exons. Cell, 1991, 64(3): 607-613

[20] GoodallGJ, WickramasingheVO. RNA in cancer. Nat Rev Cancer, 2021, 21(1): 22-36

[21] LiY, ZhengF, XiaoX, et al.. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep, 2017, 18(9): 1646-1659

[22] XieF, LiY, WangM, et al.. Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. Mol Cancer, 2018, 17(1): 144

[23] XieF, XiaoX, TaoD, et al.. circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex. Mol Ther Nucleic Acids, 2020, 22: 510-519

[24] LiuF, ZhangH, XieF, et al.. Correction: Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene, 2022, 41(35): 4183

[25] ZhangH, XiaoX, WeiW, et al.. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSalpha/ATM-p73 axis in bladder cancer. Mol Cancer, 2021, 20(1): 70

[26] WeiW, SunJ, ZhangH, et al.. Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m(6)A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer. Cancer Res, 2021, 81(24): 6142-6156

[27] Iwatani-YoshiharaM, ItoM, IshibashiY, et al.. Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay. ACS Chem Biol, 2017, 12(7): 1760-1768

[28] XuY, ZhangS, LiaoX, et al.. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappaB/bone remodeling factors signaling. Mol Cancer, 2021, 20(1): 98

[29] FilippakopoulosP, QiJ, PicaudS, et al.. Selective inhibition of BET bromodomains. Nature, 2010, 468(7327): 1067-1073

[30] TaoJ, LuQ, WuD, et al.. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep, 2011, 25(6): 1721-1729

[31] NagarajanS, RaoSV, SuttonJ, et al.. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet, 2020, 52(2): 187-197

[32] LiuX, LiZ, WangZ, et al.. Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability. Cancer Res, 2022, 82(5): 791-804

[33] MeiS, QinQ, WuQ, et al.. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res, 2017, 45(D1): D658-D662

[34] IyerG, RosenbergJE. Novel therapies in urothelial carcinoma: a biomarker-driven approach. Ann Oncol, 2018, 29(12): 2302-2312

[35] von der MaaseH, HansenSW, RobertsJT, et al.. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 2000, 18(17): 3068-3077

[36] KatagiriA, NakayamaK, RahmanMT, et al.. Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol, 2012, 25(2): 282-288

[37] ShiH, TaoT, AbrahamBJ, et al.. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv, 2020, 6(29): eaaz3440

[38] WangX, SansamCG, ThomCS, et al.. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res, 2009, 69(20): 8094-8101

[39] GarczykS, SchneiderU, LurjeI, et al.. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?. PLoS One, 2018, 13(8): e0202965

[40] LiJ, LuS, LombardoK, et al.. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma. Hum Pathol, 2016, 55: 17-23

[41] WangF, DongX, YangF, et al.. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. Front Genet, 2022, 13: 831146

[42] CondeM, FrewIJ. Therapeutic significance of ARID1A mutation in bladder cancer. Neoplasia (New York, NY), 2022, 31: 100814

[43] XuG, ChhangawalaS, CoccoE, et al.. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet, 2020, 52(2): 198-207

[44] YuC, LeiX, ChenF, et al.. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun, 2022, 13(1): 3501

[45] ConnSJ, PillmanKA, ToubiaJ, et al.. The RNA binding protein quaking regulates formation of circRNAs. Cell, 2015, 160(6): 1125-34

[46] ChanCC, DostieJ, DiemMD, et al.. eIF4A3 is a novel component of the exon junction complex. RNA, 2004, 10(2): 200-209

[47] ChenD, WangY, YangF, et al.. The circRAB3IPMediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway. Front Oncol, 2021, 11: 752573

[48] WeiY, LuC, ZhouP, et al.. EIF4A3-induced circular RNAASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling. Neuro Oncol, 2021, 23(4): 611-624

[49] FengZH, ZhengL, YaoT, et al.. EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression. Cell Death Dis, 2021, 12(11): 1025